Open AccessEfavirenz detectable in plasma 8 weeks after stopping therapy and subsequent development of non-nucleoside reverse transcriptase inhibitor-associated resistance
Author(s) -
S Tariq Sadiq,
Salim Fredericks,
Saye Khoo,
Philip Rice,
David W. Holt
Publication year - 2005
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/01.aids.0000186828.99032.60
Subject(s) - efavirenz , didanosine , reverse transcriptase inhibitor , emtricitabine , lamivudine , reverse transcriptase , medicine , nucleoside reverse transcriptase inhibitor , population , virology , pharmacokinetics , gastroenterology , pharmacology , virus , antiretroviral therapy , viral load , biology , rna , gene , hepatitis b virus , biochemistry , environmental health